Equine Genetics Market By Test Type (Parentage and Identity Testing, Inherited Disease Testing, Coat Color and Pattern Testing, Performance Trait Testing, Genomic Profiling and Diversity Testing, Reproductive and Embryo Genetic Testing); By End User (Horse Breeders and Stud Farms, Horse Owners, Veterinary Clinics and Hospitals, Equine Research Institutes and Universities, Breed Registries and Associations); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Equine Genetics Market: Genetic Screening Is Becoming a More Practical Tool in Equine Breeding and Health Management

The Global Equine Genetics Market was valued at USD 365 million in 2025 and is projected to reach USD 630 million by 2032, expanding at a CAGR of 8.1% during 2026–2032.

 

The equine genetics market is moving beyond coat-color identification and parentage verification as breeders, veterinarians and horse owners use DNA testing to reduce inherited-disease risk and support breeding decisions. UC Davis Veterinary Genetics Laboratory now offers commercial equine panels covering health disorders, coat characteristics and breed-specific conditions, showing how genetic testing has become an established veterinary service rather than a research-only tool.

 

Inherited-disease screening is one of the clearest commercial uses. The American Association of Equine Practitioners supports validated genetic testing to identify disease-associated mutations and help owners make informed decisions about breeding, purchasing and treatment. UC Davis already provides breed-specific panels, including tests for genetic conditions affecting Quarter Horses and related breeds.

 

Breeding and appearance-related testing provide another steady revenue stream. UC Davis offers individual and bundled tests for base coat color, dilution and white-pattern genetics, with its comprehensive color and pattern panel combining multiple markers in one service. Such testing is particularly relevant to breeders where predictable traits can influence mating decisions and horse valuation.

 

Research is now pushing equine genomics toward more complex health traits. The University of Minnesota is studying genetic susceptibility to equine metabolic syndrome and osteochondrosis, with the long-term aim of identifying horses at higher risk before clinical disease develops. These applications remain research-stage and require strong validation before becoming routine commercial tests.

 

Why Are Breed Registries One of the Strongest Demand Engines for the Equine Genetics Market?

Breed registries are a key driver of demand because they make DNA testing a mandatory or routine step in horse registration and breeding, rather than an optional service. For example, the American Paint Horse Association (APHA) requires genetic typing for breeding animals, DNA-based parentage verification for foals, and genetic health testing for stallions. These requirements cover conditions such as HYPP, HERDA, GBED, malignant hyperthermia, PSSM1, and OLWS, while coat color and pattern genetics can also determine eligibility for registration categories.

Similarly, the American Quarter Horse Association (AQHA) uses DNA profiling to confirm parentage and identity, and requires testing in specific breeding situations. AQHA also relies on an approved laboratory system to ensure consistency and reliability of results, which further standardizes testing demand.

The scale of these registries reinforces their market impact. AQHA reported 225,299 memberships in 2025, and its registry includes more than six million American Quarter Horses historically. This creates a large, structured population where genetic testing is embedded into official breeding and registration processes.

The Thoroughbred industry adds another consistent source of demand. The Jockey Club estimated the 2025 North American registered foal crop at 17,300, down from 17,900 in 2024, with over 17,000 live foals already reported. Each new foal typically requires identity and parentage verification, creating a recurring cycle of genetic testing.

 

How Are Inherited-Disease Tests Expanding the Commercial Role of Equine Genetics?

Inherited-disease testing is expanding the market because it helps breeders reduce genetic risk and make more informed mating decisions, especially in breeds where certain conditions are more common. The importance of these tests varies by breed and discipline, which makes targeted testing more valuable than broad, non-specific screening.

Research in American Quarter Horses shows how disease-associated variants can be concentrated in specific populations. In one study, allele frequencies in control Quarter Horses included 5.5% for PSSM1, 5.4% for GBED, 2.1% for HERDA, and 0.8% for HYPP. In some performance subgroups, such as cutting horses, the HERDA allele frequency was significantly higher, reaching 14.2%. This variation highlights why breeders often test specific lines rather than relying only on pedigree or appearance.

Newly identified variants continue to expand testing demand. For example, the MYH1 E321G variant has been reported at approximately 3.4% in a studied Quarter Horse population, with higher representation in certain performance groups such as reining and working cow horses. This supports the use of targeted genetic testing in both breeding and clinical decision-making.

Ongoing research is also adding new conditions to commercial test panels. In March 2026, UC Davis VGL introduced tests for Atypical Equine Thrombasthenia and Glanzmann Thrombasthenia, based on newly identified genetic variants. Although some of these conditions are rare, each discovery expands the range of available tests and increases opportunities for bundled testing.

 

How Is Value Created Across Testing Approaches and Key Stakeholders in Equine Genetics?

Equine Genetics Market Distribution by Test Type

Parentage and Identity Testing accounted for an estimated 28.0% market share, equivalent to USD 102.2 million in 2025, and is projected to expand at a 6.9% CAGR. It remains the largest test-type segment because DNA identity and parentage verification are integrated into registration and breeding workflows across major horse registries, providing a recurring testing base.

Inherited Disease Testing represented approximately 22.0% of the market, or USD 80.3 million in 2025, and is expected to grow at a 8.3% CAGR. Demand is supported by the expanding availability of breed-specific disease panels and the use of genetic results to reduce the risk of undesirable breeding combinations.

Coat Color and Pattern Testing held an estimated 16.0% share, valued at USD 58.4 million in 2025, and is projected to grow at a 6.7% CAGR. Testing is used by breeders to predict inherited coat characteristics and can also support registration decisions where color and pattern genetics influence breed eligibility.

Performance Trait Testing accounted for approximately 13.0% of the market, or USD 47.5 million in 2025, and is forecast to expand at a 9.1% CAGR. Growth is linked to increasing interest in genetic information related to locomotion, muscle characteristics and other inherited performance-associated traits, particularly among breeders of competition and performance horses.

Genomic Profiling and Diversity Testing represented an estimated 12.0% share, equivalent to USD 43.8 million in 2025, and is projected to record the fastest growth among test types at a 9.8% CAGR. Higher-density SNP platforms and growing attention to genetic diversity, relatedness and population management are expanding its use across breeding programs, research institutions and breed associations.

Reproductive and Embryo Genetic Testing accounted for approximately 9.0% of the market, or USD 32.9 million in 2025, and is expected to grow at a 9.5% CAGR. Demand is increasing alongside advanced equine reproduction, embryo transfer and pre-implantation genetic testing, particularly in high-value breeding programs where genetic selection can be made before establishing a pregnancy.

 

End Users Account for the Largest Share of Equine Genetics Demand

Horse Breeders and Stud Farms represented the largest end-user segment with an estimated 40.0% market share, equivalent to USD 146.0 million in 2025, and are projected to grow at a 8.3% CAGR. Their leading position reflects repeated use of parentage verification, inherited-disease panels, coat genetics and breeding-related genomic services across successive breeding cycles.

Horse Owners accounted for approximately 23.0% of the market, or USD 84.0 million in 2025, and are expected to expand at a 7.4% CAGR. Owners purchase genetic tests for identity, inherited-risk assessment, coat characteristics and breed-specific traits, particularly when testing can inform breeding, registration or horse-management decisions.

Veterinary Clinics and Hospitals represented an estimated 17.0% share, valued at USD 62.1 million in 2025, and are projected to grow at a 8.5% CAGR. Their role is expanding as genetic information is increasingly incorporated into evaluation of suspected inherited disorders and used alongside clinical findings to support breeding and health-management decisions.

Equine Research Institutes and Universities accounted for approximately 11.0% of the market, or USD 40.2 million in 2025, and are expected to register the fastest end-user growth at a 9.0% CAGR. Research programs increasingly use sequencing, high-density genotyping and population-level analysis to identify disease variants, study genetic diversity and develop new commercial assays.

Breed Registries and Associations represented an estimated 9.0% market share, equivalent to USD 32.9 million in 2025, and are projected to expand at a 6.7% CAGR. Although smaller by direct revenue contribution, registries have disproportionate influence over testing volumes because their registration, parentage and approved-laboratory policies determine which tests breeders must complete and where results can be submitted.

 

How Does Equine Genetics Demand Differ by Region?

North America as the Most Established Commercial Testing Environment

North America is the largest equine genetics market, holding a 39.0% share worth USD 142.4 million in 2025, supported by a large horse population and strong breeding infrastructure. The U.S. has about 2.41 million horses and ponies (2022 USDA data), while Canada has 183,733 horses (2021 census). Major organizations like AQHA, APHA, UC Davis VGL, and The Jockey Club integrate DNA testing into horse registration and breeding processes.

The region is highly concentrated in Thoroughbred breeding. In 2024, Kentucky-based stallions accounted for 61.4% of mares bred in North America and 66% of live foals in 2025, highlighting the dominance of key breeding hubs.

However, the Thoroughbred foal crop is declining, falling from 23,050 in 2015 to 17,210 in 2024. This slowdown means genetic testing providers increasingly rely on higher test usage per horse rather than growth in horse numbers.

 

Why Europe Is an Important Market for Pedigree and Breeding-Program Genetics

Europe’s market is supported by strong studbooks, breed societies, and an active bloodstock trade. Weatherbys plays a central role in the region, handling Thoroughbred registration in Great Britain and Ireland, while Weatherbys Scientific provides DNA-based services such as parentage verification, genetic trait testing, and genomic analysis. Europe accounted for about 29.0% of the market (USD 105.9 million) and is expected to grow at a 7.4% CAGR.

Ireland is especially important due to its strong horse identification and traceability systems. Equine census and registration reforms have improved record accuracy, and Weatherbys links DNA profiles with official foal registration. This creates a well-structured system where genetic testing is routinely integrated into breeding and pedigree verification.

 

Asia-Pacific is Developing Its Equine Genomics Infrastructure

Asia-Pacific accounted for 19.0% of the market, valued at USD 69.4 million in 2025, and is projected to grow at a 9.7% CAGR. The region has growing animal-genomics laboratory capacity, though equine-specific testing volumes are less transparent than in North America. Neogen operates genomics facilities in Australia and China, supporting regional genotyping and sequencing services.

The region is also gaining strategic importance in industry consolidation. In July 2026, Australia’s ACCC moved the proposed Zoetis acquisition of Neogen Genomics into Phase 2 review, mainly due to cattle genomics competition concerns. While not equine-specific, it highlights the increasing importance of large-scale genomic infrastructure in the region.

 

Latin America Equine Genetics Opportunities

Latin America has limited standardized equine genetic testing data, but infrastructure is gradually improving. Neogen operates a regional animal-genomics laboratory in Brazil, which helps support local testing without relying entirely on North America or Europe. The region accounts for an estimated 8.0% market share, valued at about USD 29.2 million in 2025, and is expected to grow at a CAGR of 8.5%.

Most demand is concentrated in registered breeding programs, disease-related genetic testing, and high-value performance horses, rather than widespread population-level testing.

 

Structure of the Middle East and Africa Equine Genetics Opportunity

The Middle East and Africa market is smaller and more fragmented, with demand mainly coming from Arabian horses, Thoroughbred breeding, and sport horse programs. The region is closely linked to global breeding networks, with The Jockey Club reporting 2025 foals from North American stallions born in Saudi Arabia, showing active international breeding ties. It accounts for an estimated 5.0% market share, valued at about USD 18.3 million, and is expected to grow at a 7.9% CAGR.

Growth is supported by access to international testing services, as breeders often rely on overseas laboratories. For example, UC Davis offers an Arabian Health Panel along with parentage, disease, and coat color testing, enabling breeders in the region to access advanced genetic testing even without strong local lab infrastructure.

 

How Is Competition Developing in the Equine Genetics Market?

The competitive landscape combines academic laboratories, specialist commercial testing companies, genomics-platform providers and registry-linked service organizations. Competitive advantage depends on assay breadth, scientific validation, registry acceptance, genomic infrastructure, turnaround time and the ability to convert research discoveries into routine tests.

UC Davis Veterinary Genetics Laboratory Offerings

UC Davis Veterinary Genetics Laboratory has one of the broadest equine testing portfolios and a particularly strong position where research and registry requirements overlap. Its current catalogue covers parentage verification, inherited disorders, coat colors and patterns, breed-specific health panels, embryo pre-implantation genetic diagnosis, clone validation and DMRT3 SynchroGait testing. It is also APHA's principal academic testing partner.

Its competitive advantage is the direct conversion of academic discovery into commercially orderable assays. The 2026 AET launch and the 2025 APHA registration-eligibility panel demonstrate how new research can create new paid testing services while strengthening relationships with breed registries.

 

Neogen’s Role in Equine Genomics and Potential Changes Under Zoetis Acquisition

Neogen Genomics focuses on high-density equine testing, with its GGP Equine platform offering over 70,000 SNP markers for research, genotyping, and trait analysis. It also provides identity and bioinformatics services across multiple animal species.

In March 2026, Zoetis agreed to acquire Neogen’s animal genomics business for $160 million, aiming to expand its Precision Animal Health capabilities in genotyping and sequencing. However, the deal is still under regulatory review as of August 2026, including ongoing assessments by Australia’s ACCC and New Zealand’s Commerce Commission.

 

Weatherbys Scientific's Equine Genetics Portfolio

Weatherbys Scientific combines an established role in horse registration and pedigree infrastructure with commercial laboratory services. Its equine portfolio covers parentage verification, genetic-trait testing and genomic testing using multiple genotyping platforms. The laboratory also provides broader DNA, sequencing and bioinformatics services.

Its differentiation is strongest in Thoroughbred and European pedigree markets because the wider Weatherbys organization is embedded in General Stud Book and registration workflows in Great Britain and Ireland. This makes pedigree data, DNA identity and breeding records complementary rather than isolated services.

 

Position of Animal Genetics in Direct-to-Breeder Testing

Animal Genetics has a broad direct-access testing model covering horses and other companion or breeding animals. Its equine services include coat-color analysis, inherited-disorder testing, relationship testing and other trait-based assays. The company states that its wider multi-species catalogue includes more than 300 tests.

This model is well suited to optional breeder-paid testing because owners can order specific assays without depending on a large genomic research project. Its limitation in registry-controlled applications is that availability of a technically valid assay does not automatically mean the result will be accepted by every breed association.

 

Etalon Diagnostics Strategic Relevance Despite a Smaller Registry Footprint

Etalon Diagnostics is important because APHA identifies it alongside UC Davis as an accepted partner laboratory. APHA's rules generally exclude results from non-partner laboratories, subject to limited exceptions, giving Etalon access to testing linked directly to Paint Horse registration and breeding requirements.

APHA also added MYHM to the Genetic Health Panel available through its partner laboratories in November 2024, illustrating how approved laboratories can broaden test content within an existing registry channel rather than having to acquire each breeder independently.

 

What Will Shape the Next Phase of the Equine Genetics Market?

Scientific advances will keep adding new genetic tests, but commercial success depends on whether results directly influence breeding, registration, or health decisions. For example, the 2026 AET test highlights how even rare disorders can become viable niche products when they affect a clearly defined Thoroughbred group. At the same time, research in breeds like Standardbreds and Quarter Horses is expanding the use of genomics beyond disease detection to managing genetic diversity and long-term breed health.

Registry rules remain a key driver of market control. Organizations such as APHA and AQHA require approved laboratories and standardized DNA reporting, meaning they largely determine where testing demand flows, even when multiple labs offer similar technologies.

Market growth is also limited by slower expansion in some breeding populations. For instance, North American Thoroughbred foal numbers have declined over the past decade, reducing volume for basic parentage testing. This puts pressure on labs that rely only on routine services, while those offering broader panels—such as disease screening, reproductive genetics, and genomic profiling—are better positioned.

 

Equine Genetics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 365 Million
Revenue Forecast in 2032	USD 630 Million
Overall Growth Rate	CAGR of 8.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Test Type, By End User, By Geography
By Test Type	Parentage and Identity Testing, Inherited Disease Testing, Coat Color and Pattern Testing, Performance Trait Testing, Genomic Profiling and Diversity Testing, Reproductive and Embryo Genetic Testing
By End User	Horse Breeders and Stud Farms, Horse Owners, Veterinary Clinics and Hospitals, Equine Research Institutes and Universities, Breed Registries and Associations
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Ireland, Australia, China, New Zealand, Brazil, Saudi Arabia
Market Drivers	Breed registry requirements for DNA-based parentage and identity verification, growing adoption of inherited-disease screening in breeding programs, expansion of breed-specific genetic panels, increasing use of genomic profiling and reproductive genetics in high-value horses
Customization Option	Available upon request